News

Stay up to date on the latest news and updates from Cohesion Bureau and our clients, while gaining valuable insights from our team of experts.


Insights

What’s in store in 2024? 

As we wind down for holiday season, it’s a great moment to look ahead and plan for potential opportunities.  Biotech...

12/2023

Insights

Biotech investment: is the oncology focus coming at the expense of areas with greater need? 

Cell and gene therapies are the latest investment trend in the biotech sector. But a Cohesion Bureau analysis* by Julia Schüler...

10/2023

Insights

We must reframe the discussion on Alzheimer’s disease

We’re at a pivot point in Alzheimer’s drug development, and we mustn’t let history slow us down

09/2023

Insights

Why are European companies shy of IPOs?

Investors continue to have an appetite for equities, as shown by the robust performance of the stock markets in the...

07/2023

Clients

Mithra Appoints Experienced Life Sciences Executive Christian Homsy* as Chairman

May 29, 2023 01:30 ET| Source: Mithra Pharmaceuticals Inge Beernaert appointed President of the Compensation and Nomination Committee Jacques Galloy appointed...

05/2023

Chris Maggos

Insights

Have biotech stocks bottomed out?

by Chris Maggos (published in European Biotechnology, 15.11.2022) Biotechnology was dramatically rewarded in the financial markets through much of 2020...

11/2022

Clients

AC Immune Receives FDA Fast Track Designation For Anti-Amyloid-Beta Active Immunotherapy, ACI-24.060, To Treat Alzheimer’s Disease

AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease Ongoing Phase 1b/2 ABATE...

06/2023

Clients

AC Immune Holds Annual General Meeting of Shareholders

June 23, 2023 AC Immune Holds Annual General Meeting of Shareholders Shareholders approved all resolutions as proposed by the Board...

06/2023

Clients

Kinarus Therapeutics signed CHF 1.5 million convertible loan agreement with ChaoDian (Hangzhou) Investment Management

May 11, 2023 7:00 AM Ad hoc announcement pursuant to Art. 53 LR Basel, Switzerland, May 10, 2023 – Kinarus Therapeutics...

05/2023

Clients

Vaccentis Appoints Dr. Ingrid Rauter as Chief Medical Officer and Head of Research & Development

Zurich, Switzerland, May 3, 2023 – Vaccentis AG, a clinical-stage Swiss biopharmaceutical company developing patient-individualized medicines, today announced the appointment of the experienced life...

05/2023

Clients

AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update

Lausanne, Switzerland, April 28, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases,...

04/2023

Clients

First MSCI index based Crypto ETP launched by ETC Group starts trading on XETRA

ETC Group MSCI Digital Assets Select 20 ETP (DA20) tracks performance of the top 20 digital assets, comprising around 85%...

04/2023

Clients

AC Immune To Host Key Opinion Leader Webinar On Early Diagnosis And Prevention Of Alzheimer’s Disease

Webinar to take place on Tuesday, April 18, 2023, at 10:30 AM EDT / 4:30 PM CEST  Lausanne, Switzerland, April 5, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical...

04/2023

Clients

Trobix Bio Raises $3 Million from Chartered Group to Advance Precision Microbiome Oncology Therapeutics

Netanya, Israel, March 30, 2023 – Trobix Bio, a company utilizing CRISPR, phage, and synthetic biology technologies to develop advanced precision...

03/2023